Kodiak Sciences (NASDAQ:KOD) Stock Rating Upgraded by Wall Street Zen

Posted by George Bondi on Oct 6th, 2026

Kodiak Sciences (NASDAQ:KOD – Get Free Report) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other research firms have also issued reports on KOD. Lifesci Capital boosted their price objective on Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. UBS Group lifted their target price on Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a report on Monday, September 28th. JPMorgan Chase & Co. upped their price target on Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Kodiak Sciences in a research report on Friday, July 10th. Finally, HC Wainwright upped their target price on shares of Kodiak Sciences from $58.00 to $96.00 and gave the stock a “buy” rating in a report on Monday, September 28th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $100.43.

Get Our Latest Report on Kodiak Sciences

Kodiak Sciences Stock Down 0.7%

NASDAQ KOD opened at $93.81 on Friday. The firm has a market cap of $5.90 billion, a P/E ratio of -22.39 and a beta of 2.03. The company’s 50 day moving average is $44.57 and its 200-day moving average is $40.29. Kodiak Sciences has a 12-month low of $10.94 and a 12-month high of $104.00.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). Equities analysts expect that Kodiak Sciences will post -3.97 EPS for the current year.

Insider Transactions at Kodiak Sciences

In related news, Director Bros. Advisors Lp Baker acquired 33,726 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was purchased at an average price of $85.05 per share, with a total value of $2,868,396.30. Following the completion of the purchase, the director owned 20,191,214 shares in the company, valued at $1,717,262,750.70. This trade represents a 0.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have bought 1,941,755 shares of company stock worth $156,986,026 in the last ninety days. Corporate insiders own 44.40% of the company’s stock.

Hedge Funds Weigh In On Kodiak Sciences

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Kodiak Sciences in the second quarter worth about $161,113,000. Baker BROS. Advisors LP boosted its position in shares of Kodiak Sciences by 15.1% in the 4th quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company’s stock worth $556,940,000 after purchasing an additional 2,608,696 shares in the last quarter. Jupiter Topco LLC purchased a new stake in shares of Kodiak Sciences in the 2nd quarter worth approximately $59,507,000. ICONIQ Capital LLC purchased a new stake in shares of Kodiak Sciences in the 2nd quarter worth approximately $49,345,000. Finally, Bank of America Corp DE bought a new position in Kodiak Sciences during the 2nd quarter valued at approximately $14,949,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

(Get Free Report)

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.